Why

The shift from cancer therapy to home treatment with oral oncolytics (a pill form of cancer therapy) brings a challenge in medication adherence. Especially because of complex medication regimens and high costs. This has crucial implications for patients and healthcare systems. Indeed, if a patient does not follow the medication regimen properly or stops taking it prematurely, it may actually lead to cancer recurrence and higher mortality rates. Patient support from a multidisciplinary care team is the only proven solution for promoting adherence.

What

Digital health start-up Vaalia is developing technology that helps healthcare teams do just that, by creating a personalized treatment plan, empowering patients and monitoring treatment through a digital platform. The basis for the technology is a newly built analytics platform for oral oncolytics. This will identify why and when patients stop taking cancer tablets or capsules. Based on the data, the platform predicts which patients are most likely to fail their medication regimen. It also provides the care team with targeted, personalized intervention suggestions to prevent patients from prematurely stopping their treatment.

Impact

Solutions that contribute to adherence to oral oncolytics have a potentially large impact on the health status of patients. They can also contribute to better working conditions for healthcare professionals and lower healthcare costs for society. Thus, the investment fits into Noaber's strategy of participating in meaningful companies that bring about sustainable change and improve health.

Quadruple aim approach

In doing so, Noaber uses the quadruple aim approach. This is an approach that looks at four aspects of health systems: patient experiences, health care personnel experiences, population health and per capita health care costs.